BARBARA ANN KARMANOS CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1995-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.karmanos.org
Clinical Trials
154
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (144 trials with phase data)• Click on a phase to view related trials
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
- Conditions
- HER2-negative Breast CancerHormone Receptor Positive TumorAdvanced Breast CancerMetastatic Breast Cancer
- First Posted Date
- 2025-11-13
- Last Posted Date
- 2025-11-13
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 82
- Registration Number
- NCT07227831
A Study of the TheraBionic P1 Device in Breast Cancer
- Conditions
- Breast Cancer Stage IBreast Cancer Stage IIBreast Cancer Stage IIIAHormone Receptor Positive TumorHER2-negative Breast Cancer
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT07218432
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer
- Conditions
- Metastatic Colorectal Adenocarcinoma
- Interventions
- Device: TheraBionic P1
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-11-10
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 102
- Registration Number
- NCT07130903
- Locations
- 🇺🇸
Karmanos Cancer Institute at McLaren Bay Region, Bay City, Michigan, United States
🇺🇸Karmanos Cancer Institute at McLaren Clarkston, Clarkston, Michigan, United States
🇺🇸Karmanos Cancer Institute at McLaren Flint, Flint, Michigan, United States
TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma Recurrent
- First Posted Date
- 2025-08-12
- Last Posted Date
- 2025-11-06
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 198
- Registration Number
- NCT07118202
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies
- First Posted Date
- 2025-08-01
- Last Posted Date
- 2025-11-06
- Lead Sponsor
- Barbara Ann Karmanos Cancer Institute
- Target Recruit Count
- 60
- Registration Number
- NCT07098299
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 31
- Next
News
PanTher Therapeutics Initiates Phase 1b Trial of Novel Localized Chemotherapy Film for Pancreatic Cancer
PanTher Therapeutics has dosed the first patient in a Phase 1b clinical trial of PTM-101, an innovative thin film formulation of paclitaxel designed for direct tumor placement in pancreatic ductal adenocarcinoma.
Novel BCMA-Directed CAR T-Cell Therapy Shows Promising Efficacy in Relapsed/Refractory Multiple Myeloma and AL Amyloidosis
A second-generation BCMA-directed CAR T-cell therapy, MDC-CAR-BCMA001, demonstrated remarkable efficacy in patients with relapsed/refractory multiple myeloma and AL amyloidosis, achieving a 5/6 overall response rate with 4 complete responses.
Karmanos Cancer Institute First to Prescribe FDA-Approved TheraBionic P1 for Advanced Liver Cancer
Karmanos Cancer Institute is the first worldwide to prescribe the TheraBionic P1, an FDA-approved at-home device, for advanced hepatocellular carcinoma.